MX390748B - Composiciones y metodos para tratar accidente cerebrovascular isquemico. - Google Patents

Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Info

Publication number
MX390748B
MX390748B MX2018006390A MX2018006390A MX390748B MX 390748 B MX390748 B MX 390748B MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 390748 B MX390748 B MX 390748B
Authority
MX
Mexico
Prior art keywords
sub
sup
methods
compositions
treating ischemic
Prior art date
Application number
MX2018006390A
Other languages
English (en)
Spanish (es)
Other versions
MX2018006390A (es
Inventor
David Elmaleh
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2018006390A publication Critical patent/MX2018006390A/es
Publication of MX390748B publication Critical patent/MX390748B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018006390A 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico. MX390748B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
MX2018006390A MX2018006390A (es) 2019-02-14
MX390748B true MX390748B (es) 2025-03-21

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006390A MX390748B (es) 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
CA3084593A1 (en) * 2017-12-04 2019-06-13 The General Hospital Corporation Cromolyn compositions and methods thereof
KR20200143710A (ko) * 2018-04-09 2020-12-24 더 제너럴 하스피탈 코포레이션 근위축 측삭 경화증 및 관련 장애의 치료를 위한 조합 요법
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND ALPHA-LACTOSE
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
RU2428987C2 (ru) * 2004-08-30 2011-09-20 Сео Хонг Ю Нейрозащитное действие растворимой урсодезоксихолевой кислоты в моделях фокальной ишемии
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2391618B1 (en) * 2009-01-29 2019-04-03 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3235509A1 (en) * 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
KR20110130463A (ko) * 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
JP6499077B2 (ja) * 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
CA2913235C (en) * 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
CA2928028A1 (en) * 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9962363B2 (en) * 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Also Published As

Publication number Publication date
JP2018538273A (ja) 2018-12-27
CN108472275A (zh) 2018-08-31
US20180344682A1 (en) 2018-12-06
MX2018006390A (es) 2019-02-14
US20220125753A1 (en) 2022-04-28
EP3380095A1 (en) 2018-10-03
CA3005909A1 (en) 2017-06-01
AU2016359674A1 (en) 2018-06-14
KR20180081812A (ko) 2018-07-17
EP3380095B1 (en) 2022-01-05
EP3380095A4 (en) 2019-10-23
WO2017091644A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201890752A1 (ru) Способ получения противогрибковых соединений
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
MX378499B (es) Compuestos antifungicos.
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
ECSP16067303A (es) Heteroarilos y usos de estos
EP3331880A4 (en) N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201792433A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
MX381344B (es) Compuestos antifungicos y procesos para la fabricacion.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201691141A1 (ru) Соединения против ccr6
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX382175B (es) Composiciones de profármaco de monometilfumarato
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
EA201992421A1 (ru) Способ получения озанимода
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds